Prolactin hormone exerts anti-tumorigenic effects in HER-2 overexpressing breast cancer cells through regulation of stemness

Agarwal, 2016, Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer, Oncologist., 21, 535, 10.1634/theoncologist.2015-0502 Al-Hajj, 2003, Prospective identification of tumorigenic breast cancer cells, Proc. Natl. Acad. Sci. U. S. A., 100, 3983, 10.1073/pnas.0530291100 Baselga, 1996, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer, J. Clin. Oncol., 14, 737, 10.1200/JCO.1996.14.3.737 Charafe-Jauffret, 2009, Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature, Cancer Res., 69, 1302, 10.1158/0008-5472.CAN-08-2741 Chen, 2015, The many faces of prolactin in breast cancer, Adv. Exp. Med. Biol., 846, 61, 10.1007/978-3-319-12114-7_3 Chen, 1999, A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis, Clin. Cancer Res., 5, 3583 Chen, 2002, In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R, Int. J. Oncol., 20, 813 Cheng, 2017, A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy, Oncotarget., 8, 103327, 10.18632/oncotarget.21872 Clevenger, 2003, The role of prolactin in mammary carcinoma, Endocr. Rev., 24, 1, 10.1210/er.2001-0036 Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J. Clin. Oncol., 17, 2639, 10.1200/JCO.1999.17.9.2639 Cookson, 2012, Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis, J. Psychopharmacol., 26, 42, 10.1177/0269881112442016 Croker, 2012, Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells, Breast Cancer Res. Treat., 133, 75, 10.1007/s10549-011-1692-y De Boer, 2008, Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events, Oncogene., 27, 4261, 10.1038/onc.2008.74 Duru, 2012, HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells, Clin. Cancer Res., 18, 6634, 10.1158/1078-0432.CCR-12-1436 Eyler, 2008, Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis, J. Clin. Oncol., 26, 2839, 10.1200/JCO.2007.15.1829 Fang, 2012, CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms, J. Biol. Chem., 287, 36593, 10.1074/jbc.M112.365999 Frank, 2010, The therapeutic promise of the cancer stem cell concept, J. Clin. Invest., 120, 41, 10.1172/JCI41004 Fumagalli, 2011, CD44+ CD24−/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines, Pharmacogenomics., 12, 12 Gajria, 2011, HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies, Expert. Rev. Anticancer. Ther., 11, 263, 10.1586/era.10.226 Galbaugh, 2010, Prolactin receptor-integrin cross-talk mediated by SIRPalpha in breast cancer cells, Mol. Cancer Res., 8, 1413, 10.1158/1541-7786.MCR-10-0130 Galsgaard, 2009, Re-evaluation of the prolactin receptor expression in human breast cancer, J. Endocrinol., 201, 115, 10.1677/JOE-08-0479 Ginestier, 2007, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome, Cell Stem Cell, 1, 555, 10.1016/j.stem.2007.08.014 Ginsburg, 1995, Prolactin synthesis and secretion by human breast cancer cells, Cancer Res., 55, 2591 Goffin, 2015, The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications, Expert Opin. Ther. Targets, 19, 1229, 10.1517/14728222.2015.1053209 Hachim, 2016, Prolactin receptor expression is an independent favorable prognostic marker in human breast Cancer, Appl. Immunohistochem. Mol. Morphol., 24, 238, 10.1097/PAI.0000000000000178 Hachim, 2016, A favorable role of prolactin in human breast cancer reveals novel pathway based gene signatures indicative of tumor differentiation and favorable patient outcome: prolactin-induced mammary differentiation program in breast cancer prognosis, Hum. Pathol., 53, 142, 10.1016/j.humpath.2016.02.010 Hennighausen, 2005, Information networks in the mammary gland, Nat. Rev. Mol. Cell Biol., 6, 715, 10.1038/nrm1714 Hu, 2006, The molecular portraits of breast tumors are conserved across microarray platforms, BMC Genomics, 7, 96, 10.1186/1471-2164-7-96 Incorvati, 2013, Targeted therapy for HER2 positive breast cancer, J. Hematol. Oncol., 6, 38, 10.1186/1756-8722-6-38 Inic, 2014, Difference between luminal a and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information, Clin. Med. Insights Oncol., 8, 107, 10.4137/CMO.S18006 Liu, 2012, Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERalpha- breast cancer, Proc. Natl. Acad. Sci. U. S. A., 109, 5832, 10.1073/pnas.1201105109 Liu, 2014, Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts, Stem Cell Rep., 2, 78, 10.1016/j.stemcr.2013.11.009 Liu, 2015, Prolactin/Jak2 directs apical/basal polarization and luminal linage maturation of mammary epithelial cells through regulation of the Erk1/2 pathway, Stem Cell Res., 15, 376, 10.1016/j.scr.2015.08.001 Lopez-Ozuna, 2016, Prolactin pro-differentiation pathway in triple negative breast cancer: impact on prognosis and potential therapy, Sci. Rep., 6, 10.1038/srep30934 Luque-Cabal, 2016, Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it, Clin. Med. Insights Oncol., 10, 21 Ma, 2016, Functional roles of sialylation in breast cancer progression through miR-26a/26b targeting ST8SIA4, Cell Death Dis., 7, e2561, 10.1038/cddis.2016.427 Majumdar, 2013, Hyperprolactinemia, J. Hum. Reprod. Sci., 6, 168, 10.4103/0974-1208.121400 Marcato, 2011, Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis, Stem Cells, 29, 32, 10.1002/stem.563 Martin-Castillo, 2015, Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas, Oncotarget., 6, 32317, 10.18632/oncotarget.6094 Menard, 2001, HER2 as a prognostic factor in breast cancer, Oncology., 61, 67, 10.1159/000055404 Morimoto, 2009, Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression, Cancer Sci., 100, 1062, 10.1111/j.1349-7006.2009.01151.x Nitze, 2013, Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer, Breast Cancer Res. Treat., 142, 31, 10.1007/s10549-013-2731-7 Nouhi, 2006, Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells, Cancer Res., 66, 1824, 10.1158/0008-5472.CAN-05-2292 Oakes, 2008, Prolactin regulation of mammary gland development, J. Mammary Gland Biol. Neoplasia, 13, 13, 10.1007/s10911-008-9069-5 Petty, 1999, Prolactin and antipsychotic medications: mechanism of action, Schizophr. Res., 35, S67, 10.1016/S0920-9964(98)00158-3 Peuskens, 2014, The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review, CNS Drugs., 28, 421 Ricardo, 2011, Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype, J. Clin. Pathol., 64, 937, 10.1136/jcp.2011.090456 Rizzolio, 2011, Multifaceted role of neuropilins in cancer, Curr. Med. Chem., 18, 3563, 10.2174/092986711796642544 Sato, 2014, Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression, Oncogene., 33, 2215, 10.1038/onc.2013.172 Schnitt, 2010, Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy, Mod. Pathol., 23, S60, 10.1038/modpathol.2010.33 Schroeder, 2003, Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL, Endocrinology., 144, 5300, 10.1210/en.2003-0826 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science., 235, 177, 10.1126/science.3798106 Smalley, 2003, Stem cells and breast cancer: a field in transit, Nat. Rev. Cancer, 3, 832, 10.1038/nrc1212 Smith, 2005, Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability, Br. J. Cancer, 93, 719, 10.1038/sj.bjc.6602779 Sultan, 2005, Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells, Oncogene., 24, 746, 10.1038/sj.onc.1208203 Tomita, 2016, Aldehyde dehydrogenase 1A1 in stem cells and cancer, Oncotarget., 7, 11018, 10.18632/oncotarget.6920 Tran, 2011, Luminal-B breast cancer and novel therapeutic targets, Breast Cancer Res., 13, 221, 10.1186/bcr2904 Vayrynen, 2016, Clinical impact and network of determinants of tumour necrosis in colorectal cancer, Br. J. Cancer, 114, 1334, 10.1038/bjc.2016.128 Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J. Clin. Oncol., 20, 719, 10.1200/JCO.2002.20.3.719 Wang, 2013, PPARgamma maintains ERBB2-positive breast cancer stem cells, Oncogene., 32, 5512, 10.1038/onc.2013.217 Xu, 2015, Aldehyde dehydrogenases and cancer stem cells, Cancer Lett., 369, 50, 10.1016/j.canlet.2015.08.018 Zhang, 2015, Residue 146 regulates prolactin receptor folding, basal activity and ligand-responsiveness: potential implications in breast tumorigenesis, Mol. Cell. Endocrinol., 401, 173, 10.1016/j.mce.2014.12.006